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Abstract
Background—Tumor cell tissue factor (TF)-initiated coagulation supports hematogenous
metastasis by fibrin formation, platelet activation, and monocyte/macrophage recruitment. Recent
studies identified host anticoagulant mechanisms as a major impediment for successful
hematogenous tumor cell metastasis.
Objective—Here we address mechanisms that contribute to enhanced metastasis in
hyperthrombotic mice with functional thrombomodulin deficiency (TMPro mice).
Methods—Pharmacological and genetic approaches were combined to characterize relevant
thrombin targets in a mouse model of experimental hematogenous metastasis.
Results—TF-dependent, but contact pathway-independent syngeneic breast cancer metastasis
was associated with marked platelet hyper-reactivity and formation of leukocyte-platelet
aggregates in immune-competent TMPro mice. Blockade of CD11b or genetic deletion of platelet
glycoprotein Ibα excluded contributions of these receptors to enhanced platelet-dependent
metastasis in hyperthrombotic mice. Mice with very low levels of the endothelial protein C
receptor (EPCR) did not phenocopy the enhanced metastasis seen in TMPro mice. Genetic deletion
of the thrombin receptor PAR1 or endothelial thrombin signaling targets alone did not diminish
enhanced metastasis in TMPro mice. Combined deficiency of PAR1 on tumor cells and the host
reduced metastasis in TMPro mice.
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Conclusions—Metastasis in the hyperthrombotic TMPro mouse model is mediated by platelet
hyper-reactivity and contributions of PAR1 signaling on tumor and host cells.
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Introduction
A prothrombotic state is one of the hallmarks of malignancies. Tissue factor (TF), the
cellular initiator of the coagulation cascade, triggers local and remote thrombotic
complications in cancer patients [1]. TF-dependent thrombin generation influences multiple
cellular interactions in tumor microenvironments [2]. In spontaneous breast cancer
progression and human xenograft models in the microenvironment of the mammary gland,
tumor cell-expressed TF is important for gene expression patterns that regulate angiogenesis
and tumor growth. These effects are thrombin-independent and involve cell signaling
mediated by the TF cytoplasmic domain, activation of the protease activated receptor (PAR)
2, and integrin ligation [3–5]. TF also plays a role during intravasation of tumor cells, an
important first step in tumor dissemination to distant sites [6]. In contrast to primary tumor
growth, TF procoagulant activity is crucial for successful metastasis [7] by improving
intravascular tumor cell survival through fibrin formation [8], platelet-dependent protection
from natural killer cell attack [9;10], and priming of the metastatic niche to facilitate
monocyte/macrophage interactions with tumor-associated microthrombi [11]. The platelet
thrombin receptors glycoprotein (GP) Ibα [12] and PAR4 [10] contribute to metastasis. In
addition, the thrombin receptor PAR1 expressed by melanoma cells contributes to
experimental metastasis [13;14], but deletion of PAR1 has no measurable effect on
spontaneous metastasis in other tumor models [15].
Genetic or pharmacological perturbations of clinically relevant host anticoagulant
mechanisms in mice influence the efficiency of metastasis. Vascular overexpression of the
endothelial cell protein C receptor (EPCR) or treatment with activated protein C (aPC)
reduces metastasis, whereas blocking endogenous aPC increases metastasis associated with
endothelial barrier disruption [16;17]. Consistent with local anticoagulant control of tumor
cell generated thrombin, mice carrying the aPC-resistant factor VLeiden show increased
hematogenous metastasis [18]. In addition, spontaneous and experimental metastasis is
markedly enhanced in thrombomodulin Glu404/Pro mutant (TMPro) mice [19] that mimic
inflammation-induced functional thrombomodulin deficiency by exhibiting reduced
thrombin binding and PC activation [20]. Deficiency of thrombomodulin reduces generation
of thrombin-activated fibrinolysis inhibitor (TAFI), but TAFI-deficient mice have no
apparent alterations in metastasis [21]. Taken together with the crucial role of prothrombin
for enhanced metastasis in TMPro mice [19], these studies suggest that thrombin
neutralization by the endothelium and/or local aPC generation counteract tumor cell
prometastatic abilities, but the downstream targets for thrombin remain incompletely
defined.
Understanding prometastatic mechanisms in murine models has clinical implications for
deciphering roles of the hemostatic system and prothrombotic states in tumor progression.
Since factor VIII and von Willebrand Factor (vWF) are important for metastasis [18;22], we
here evaluated the relative contributions of contact and TF pathway initiation to
experimental hematogenous metastasis. We further analyzed the role of platelet receptors in
the pro-metastatic phenotype of TMPro mice and capitalized on the unique absence of PAR1
from murine platelets [23] to identify PAR1 signaling on both tumor and host cells as a
contributor to metastasis in hyperthrombotic TMPro mice.
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Rat IgG2b anti-mouse CD11b antibody (M1/70), rat IgG1 anti-mouse PSGL-1 antibody
(4RA10), and rat IgG2b control antibody (LTF-2) was purchased from BioXCell (West
Lebanon, NH). The anti-thrombotic mouse anti-mouse factor (F) XI (14E11) monoclonal
antibody blocks the activation of FXI by FXIIa [24] and is a potent inhibitor of thrombosis
in contact pathway dependent models of thrombosus formation in mice [25]. Annexin 5 was
expressed (plasmid a kind gift from Dr. Martin (The Smurfit Institute, Dublin, Ireland)),
purified and labeled with Alexa488. Rat anti-mouse GPIbα antibody (5A7) was raised
against recombinant mouse GPIbα ectodomain, screened for selectivity of mouse versus
human GPIbα, and confirmed for activity to deplete platelets in vivo. Alexa 647 rat IgG2a
anti-mouse TF (21E10) and rabbit anti-mouse TF polyclonal antibody (R8084) were used
for FACS and Western-blotting, respectively [25].
Tumor models
Mammary carcinoma cells (line 3503) were established from PyMT-TFflox mice generated
by crossing TFflox and PyMT mice on a C57BL/6 background [26;27]. PyMT-TFflox cells
were transduced with adenovirus vector expressing cre recombinase on two consecutive
days to delete TF. The TF knockout cells were reconstituted with murine full-length or
alternatively-spliced TF (asTF) using pRetroX-IRES-DsRedExpress Vector (Clontech
Laboratories, Mountain View, CA), as described [3]. Reconstitution was confirmed by
Western blotting of whole cell lysates and supernatants fractionated into microparticles
(MP) and soluble fractions. PAR1−/− cells were established from independent PyMT
PAR1−/− mice, as described [15]. Cells were cultured in L-15 medium with 10% FCS, 10
μg/ml insulin, and 10 mM L-glutamine.
Mice
Animal experiments were performed under approved protocols of the Institutional Animal
Care and Use Committee (IACUC) of the Scripps Research Institute. Mice were
backcrossed into the C57BL/6 strain. EPCRlow hypomorphic mice express very low levels
of EPCR [28]. TMPro mice [20] were crossed with PAR1−/− mice [15;29] or Slc7a2−/− mice
[30] to generate TMPro/Slc7a2−/− mice and TMPro/PAR1−/− mice, respectively. Platelets
were isolated from murine GPIbα-deficient mice that carried transgenes for platelet-specific
expression of either human GPIbα or a chimeric molecule in which the extracellular domain
of GPIbα was replaced by the IL-4 receptor ectodomain (IL-4R).
Experimental hematogenous metastasis model
Typically, 8 × 104 PyMT-TFflox cells were injected into the lateral tail vein of TMPro mice
and 2 × 105 cells into other strains that did not carry the TM mutation and mice were
sacrificed after 21 days. For PyMT-PAR1−/− cells (2×105 cells/mouse), metastasis was
scored after 35 days. The wet lung weights were recorded and lungs were fixed in Bouin’s
solution for counting tumor foci on the lung surface.
Tumor cell quantification in lungs
Tumor cell retention in the lungs was measured 24 hours after injection. Minced lung tissue
(20 mg) was extracted in 500 μl of alkaline lysis buffer (25 mM NaOH, 0.2 mM EDTA, pH
12) overnight at 95°C, neutralized with 500 μl 40 mM Tris-HCl, pH 5, and 10 μl of lung
DNA sample or DNA extracted from a defined numbers of tumor cells were used for
Taqman amplification of the PyMT transgene using forward primer 5′-
CTGAGCCCGATGACAGCATA-3′, reverse primer 5′-
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TCTTGGTCGCTTTCTGGATACA, and the Taqman probe 5′-[6-
FAM]CCCCGGACCCCCCCAGAACT[tamra-Q]-3′. Tumor cells in the lungs were
quantified based on the tumor cell standard and total lung weights.
Antibody treatments and fibrinogen depletion
Mice were given intraperitoneal injections of 2 μg/g body weight of anti-FXI antibody
14E11, 100 μg of monoclonal anti-GPIbα antibody 5A7, 200 μg of monoclonal anti-CD11b
antibody M1/70, 100 μg of monoclonal anti-PSGL-1 (CD162) antibody, or the same doses
of control IgG at 4 and 24 hours prior to the tumor cell inoculation. Fibrinogen was depleted
by intravenous injection of 25 KU/kg recombinant batroxobin (Creative Biomart, NY) from
the snake venom of Bothrops atrox [31], 1 hour prior to tumor cell injection. Fibrinogen
depletion was monitored spectrophotometrically by absorbance changes at 350 nm of 100 μl
of 10-fold diluted citrated plasma samples mixed with 100 μl of thrombin (100 nM).
Platelet experiments
Platelets were depleted with anti-mouse GPIbα antibody (5A7) prior to reconstitution with
platelets expressing human GPIbα (hGPIbα) or IL-4R, both of which were not affected by
the depleting antibody. For platelet preparation, blood was collected from the retro-orbital
plexus of anesthetized mice and mixed with one-tenth volume 3.2% sodium citrate and
diluted in Tyrode’s solution pH 6.5 for isolation of platelets that were resuspended in
Tyrode’s solution, pH 7.4 for intravenous injection at doses of 4–6×108/mouse. Mouse
platelets were stained with annexin 5 in diluted whole blood (1:100 in Tyrode’s Buffer, 5
mM CaCl2 versus 10 mM EDTA negative controls) obtained from untreated mice or 2 hours
after injection of 2 × 105 PyMT-TFflox cells or buffer and analyzed with a LSRII, using
gating based on size and collection of a minimum of 10,000 events. Platelet-leukocyte
aggregates (PLA) were quantified in diluted whole blood stained with anti-mouse CD45 and
CD42b as double positive events in the CD45 population. Platelet counts were obtained with
a Hemavet 950LV hematological analyzer (Drew Scientific, Dallas, TX).
Functional characterization of tumor cells
FXa generation was measured on cell monolayers using a discontinuous chromogenic assay
with Spectrozyme FXa (American Diagnostica, Stamford, CT). Western blotting used a
rabbit anti-mouse TF polyclonal antibody (8084) and integrin β1 or β actin as loading
controls.
Statistical analysis
Data are presented as mean ± SD. We used GraphPad Prism version 4.03 for the Student
unpaired t test and analysis of variance (ANOVA). Multiple comparisons by ANOVA
included the Bonferroni posttest.
Results
TF-dependent metastasis in TMPro mice is independent of the contact pathway
We have used the PyMT model of spontaneous murine breast cancer development to study
TF-dependent primary tumor growth [3;15]. Similar to various other tumor models [19],
PyMT breast cancer cells injected at the same dose metastasized more efficiently in TMPro
mice (Fig. 1A). To confirm the procoagulant contributions of tumor cell TF, we deleted TF
from established metastatic PyMT-TFflox breast cancer populations using in vitro treatment
with cre recombinase. Western blotting (Fig. 1B), FACS analysis (Fig. 1C), and FXa
generation assay (Fig. 1D) confirmed highly efficient deletion of TF. Pulmonary metastasis
was markedly reduced following TF deletion and injection of the same number of TF-
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depleted cells into WT or TMPro mice (Fig. 1E). Metastatic burden was insignificantly
increased in TMPro mice relative to WT, which may be caused by the presence of alternative
tumor procoagulants and/or conditioning of the metastatic niche due to the procoagulant
state of TMPro mice [11]. TF-deficient cells were reconstituted with either full-length (flTF)
or alternatively spliced TF (asTF) (Fig. 1F). Testing of these lines confirmed that
procoagulant flTF, but not asTF [32] was required for metastasis (Fig. 1G). These data
indirectly support the concept that asTF mainly promotes tumor progression through
coagulation-independent effects on integrins in the context of tumor angiogenesis and
primary tumor expansion [4;33;34].
The contact pathway contributes to TF-dependent thrombosis [24;25], but the role of the
contact pathway in metastasis of hyperthrombotic TMPro mice is unknown. WT or TMPro
mice were intravenously injected with PyMT-TFflox breast cancer cells at different doses, in
order to compensate in part for the diminished metastasis in WT mice. We blocked FXIIa-
mediated FXI activation with the anti-FXI antibody 14E11, given prior to tumor cell
injection at an 8-fold higher dose than the one required for complete inhibition of
experimental thrombosis [25]. This antibody had no effect on the markedly enhanced
metastasis in TMPro mice (Fig. 1H). These results provided new evidence that tumor cell TF
drives experimental metastasis independent of contact phase activation in TMPro mice.
Increased platelet activation in TMPro mice
TF-initiated thrombin generation supports tumor cell homing and survival through fibrin
formation [8], but blockade of endogenous PC renders the metastatic process apparently
independent of fibrinogen by poorly understood mechanisms [35]. Similarly, fibrinogen
depletion by > 98% with a single dose (25KU/kg) of recombinant batroxobin attenuated
metastasis in WT, but produced no statistically significant reduction in hyperthrombotic
TMPro mice (Fig. 2A). These data indicated that the hypermetastatic phenotype of TMPro
mice was not primarily caused by increased local fibrin network formation. Surprisingly,
control experiments showed that fibrinogen depletion produced a marked drop in platelet
counts specifically in TMPro mice (Fig. 2B). Platelet counts were indistinguishable between
WT and TMPro mice at baseline and fibrinogen depletion had no effect on platelet counts in
WT mice (Fig. 2B). These data indicate that fibrinogen deficiency produces complex effects
in hyperthrombotic mouse models that make it difficult to study specific contributions of
fibrinogen or fibrin to the metastatic process.
We reasoned that depletion of the abundant thrombin substrate and regulator fibrinogen [36]
led to increased activation of platelets that in turn compensated for the decreased fibrinogen
levels during metastasis. This conclusion raised the question whether platelet hyper-
reactivity occurred following injection of procoagulant tumor cells. Platelet surface
phosphatidylserine detected by annexin 5 staining was increased in TMPro mice under
unchallenged conditions, but this platelet population was no longer seen after tumor cell
injection (Fig. 2C). Instead, a drop in platelet counts (Fig. 2D) and markedly increased
numbers of platelet-leukocyte aggregates (Fig. 2E) were observed following tumor cell
injection specifically into TMPro mice. Thus, increased platelet activation is a previously
unidentified effect of amplified thrombin generation in this hyperthrombotic mouse strain.
Leukocyte interaction with platelet GPIbα is not required for enhanced metastasis in TMPro
mice
Given the increased platelet-leukocyte aggregates and prior studies implicating both GPIbα
[12] and CD11b+ monocyte/macrophages interacting with blood clots in the efficiency of
metastasis [11], we asked whether the interaction between platelet-expressed GPIbα and
CD11b [37] contributed to enhanced metastasis of breast cancer cells in TMPro mice. We
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blocked CD11b with antibody M1/70 administered at a dose 4-fold higher than that
previously used to inhibit myeloid cell recruitment in tumor growth experiments [38], and
confirmed prior data that this antibody had no effect on leukocyte counts, but abolished
CD11b staining on blood white blood cells isolated from specific antibody-treated mice.
CD11b blockade had no effect on metastasis in the depicted and an independent experiment
in TMPro mice (Fig. 3A).
In order to exclude redundancy in leukocyte recruitment pathways due to the hyper-reactive
platelets of TMPro mice, we also blocked PSGL-1 (CD162), an important leukocyte counter-
ligand for platelet P selectin. Note that PSGL-1 was not expressed by our tumor cells and
that carbohydrate ligands on carcinoma cell mucins are known to initiate prometastic,
platelet-dependent pathways involving PSGL-1 [39]. Treating mice with anti-mouse
PSGL-1 antibody at previously used inhibitory doses [40] alone or in combination with anti-
CD11b antibody M1/70 (Fig. 3B) had no effect on metastasis in TMPro mice relative to
control antibody-treated mice.
We used a genetic strategy to further address roles of platelet-expressed GPIbα as a counter-
receptor for CD11b. We generated a monoclonal antibody (5A7) to murine GPIbα without
cross-reactivity to human GPIbα and confirmed the efficiency of the antibody to achieve
prolonged platelet depletion in WT mice for 24–48 hours (Fig. 3C). Depleted mice were
transfused with platelets expressing either human GPIbα (hGPIbα) or a chimeric protein of
the IL-4R extracellular domain replacing the murine GPIbα ectodomain to prevent the
Bernard-Soulier phenotype of GPIbα-deficient platelets [41]. Reconstitution with either
platelet source restored platelet counts in accordance with the administered dose (Fig. 3C).
Depletion of platelets markedly reduced the number of tumor cells retained in the lungs 24
hours after injection and lung metastasis in WT mice (Fig. 3D, E) and metastasis in TMPro
mice (Fig. 3E), as previously reported [19]. Reconstitution of platelet-depleted mice with
platelets expressing either hGPIbα or the IL-4R chimera restored metastasis to similar levels
(Fig. 3E), with an insignificant trend towards higher metastasis when depleted WT mice
were reconstituted with GPIbα replete platelets expressing the human receptor. Thus, both
pharmacological and genetic approaches found no contribution of the GPIbα-CD11b
interaction to platelet-dependent metastasis in TMPro mice.
PAR1 signaling contributes to enhanced metastasis in TMPro mice
The mutation introduced in TMPro mice impairs both thrombin binding and activation of the
PC pathway that is dependent on EPCR [20]. Endothelial overexpression of EPCR
suppresses metastasis [16] and deficiency of EPCR increases vascular leak in inflammation
[42], but metastasis was not enhanced in EPCRlow mice, in contrast to TMPro mice (Fig.
4A). Endothelial cell EPCR-aPC-PAR1 and thrombin-PAR1 signaling produce opposing
gene expression changes, including the cationic amino acid transporter Slc7a2. Slc7a2 is
induced by thrombin, but downregulated by aPC signaling [43], and Slc7a2 regulates nitric
oxide production, previously implicated in tumor progression [27]. We tested whether loss
of this thrombin-PAR1 signaling target attenuated metastasis. Metastasis in Slc7a2−/− hosts
was indistinguishable from WT controls and, importantly, Slc7a2-deletion did not correct
the prometastatic phenotype of TMPro mice, as seen with platelet depletion (Fig. 4B). Thus,
increased metastasis in TMPro mice was independent of EPCR and one of the possible
downstream targets of endothelial cell thrombin-PAR1 signaling.
In the mouse, thrombin activates platelets through PAR4 and PAR1 expressed by other host
cells is dispensable for metastasis in mice without coagulation abnormalities [10]. As seen
with other tumor models [10], breast cancer cell metastasis was not significantly impaired in
PAR1−/− mice (Fig. 4C). In addition, metastasis was not different between TMPro and
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TMPro/PAR1−/− mice (Fig. 4D). Thus, loss of host thrombin-PAR1 signaling alone was
insufficient to attenuate increased metastasis in TMPro mice.
In addition, tumor cell PAR1 signaling has been implicated in the prometastatic phenotype
of melanoma cells [13;14]. We next addressed whether increased thrombin levels in TMPro
mice increased metastasis through signaling involving PAR1 on tumor cells, using
thrombin-insensitive breast cancer cell lines from PyMT-PAR1−/− mice [15]. Two
independent PyMT-PAR1−/− cell populations expressed similar TF antigen (Fig. 5A, C) and
activity (Fig. 5B). As seen with PAR1-expressing WT control, each of the PyMT-PAR1−/−
lines showed markedly enhanced metastasis in TMPro mice when the same cell dose was
injected into mutant or WT mice (Fig. 5D). Thus, thrombin-mediated activation of PAR1 on
tumor cells also did not account for enhanced metastasis in TMPro mice.
Endothelial cell PAR1 signaling induces the chemokine CCL2 (MCP-1) [44] that is pivotal
for efficient metastasis [45]. Because both host- and tumor cell-derived CCL2 contribute to
metastasis [45], we next addressed the possibility that host- and tumor cell-expressed
PAR1similarly played redundant roles in thrombin-dependent metastasis in TMPro mice. We
first injected a fairly high tumor cell dose of PAR1-deficient tumor cells and found an
insignificant trend towards decreased metastasis in PAR1−/− mice (Fig. 5E). Moreover,
metastasis of PAR1-deficient tumor cells injected into TMPro/PAR1−/− was significantly
reduced in two independent experiments relative to TMPro controls (Fig. 5E). However, the
inhibitory effect of combined host and tumor cell PAR1 deficiency on the hypermetastatic
phenotype of TMPro mice was only partial, suggesting that multiple thrombin targets
contribute to enhanced metastasis in this hyperthrombotic mouse model.
Discussion
This study provides new insight into the roles of thrombin targets in enhancing TF-
dependent metastasis in hyperthrombotic mice. We uncovered increased baseline PS
exposure on platelets in TMPro mice and a marked increase in platelet-leukocyte aggregates
following the prothrombotic challenge of injecting tumor cells. These results suggest that
increased platelet activation can become a predominant prometastatic mechanism in
prothrombotic states. Increased platelet-leukocyte aggregates were seen in mice with
circulating tumor cells. We therefore assessed with pharmacological and genetic approaches
the contributions of a key receptor interaction bridging platelets and leukocytes that had
previously been implicated in metastasis, i.e. GPIbα and CD11b [11;12][37].
We found no apparent contribution of these receptors to enhanced metastasis in TMPro mice.
A subtle increase in metastasis was seen when WT mice were reconstituted with platelets
expressing human GPIbα versus IL-4R chimera platelets with normal size and shape, while
complete GPIbα deficiency had previously been shown to result in a pronounced decrease in
metastasis [12]. Since genetic deficiency of CD11b also had a more pronounced effect on
metastasis [11] that contrasted with the lack of inhibition by our short term pharmacological
blockade of CD11b, it is tempting to speculate that leukocyte-platelet interactions in
immune competent mouse models may influence metastasis by more long term effects on
leukocyte populations and/or priming of metastatic niches. It will be of interest for future
studies to study alternative pathways that support platelet-leukocyte interactions as well as
address paracrine and adhesive interactions between tumor cells and platelets as potential
factors that enhance metastasis in hyperthrombotic mouse models [46].
TMPro mice are defective in both aPC generation and local neutralization of thrombin
generated intravascularly, but metastasis was neither enhanced by deletion of the aPC co-
signaling receptor EPCR nor reduced in TMPro mice by genetic deletion of PAR1 on host
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cells or PAR1 downstream endothelial targets. However, deficiency of PAR1 in both, tumor
and host cells, reduced metastasis significantly. These data are in line with prior data that
implicated tumor cell PAR1 in melanoma metastasis [13;14] and indicate that host and
tumor cell PAR1 can mediate partially redundant functions in breast cancer cell metastasis.
The PAR1-inducible and prometastatic chemokine CCL2 has redundant sites of synthesis in
the tumor and host cell compartments [45], but more extensive studies will be required to
determine whether CCL2 is one of the relevant PAR1 target during the metastatic process.
Since PAR4, but not PAR1, is the relevant thrombin receptor on mouse platelets, the partial
reduction of metastasis following PAR1 deletion in TMPro mice indicates that the
hyperthrombotic state of TMPro mice favors multiple tumor-promoting pathways in addition
to thrombin-driven interactions of platelets with tumor cells.
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Fig. 1. Extrinsic coagulation activation solely promotes metastasis in WT and TMPro mice
(A) Metastasis of PyMT breast cancer cells in WT and TMPro mice, *p<0.0001, t-test. (B, C,
D) Efficient deletion of TF by cre recombinase transfection of PyMT-TFflox breast cancer
cells by Western blotting (B), FACS analysis (C), and FXa generation assay (D), * p<0.001,
t-test. (E) Pulmonary metastases counts and representative views of wild type (WT) and
TMPro mice challenged with 2 × 105 PyMT-TFflox control or cre+ adenovirus-treated cells, *
p<0.001, ANOVA. (F) Reconstitution of flTF and asTF in cre recombinase-treated PyMT-
TFflox cells verified by Western blotting of total cell lysates (cells), conditioned medium
(CM) and the derived MP fraction (MP) and MP-depleted supernatant (Sup). (G) Pulmonary
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metastasis of cells reconstituted with full-length murine TF (mTF) or alternatively spliced
TF (asTF). Control cells were transduced with empty retrovirus (mock), *p<0.001,
ANOVA. (H) Metastasis in mice with or without inhibition of contact pathway-dependent
FXI activation with anti-XI antibody 14E11; comparison of treated and untreated mice by t-
test, p > 0.05.
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Fig. 2. TMPro mice have hyper-reactive platelets
(A) Metastases in fibrinogen-depleted WT or TMPro mice challenged with 2 × 105 or 8 ×
104 PyMT-TFflox cells, respectively; * p = 0.00034 for WT and p = 0.069 for TMPro, t-test.
(B) Effect of fibrin depletion on platelet counts, mean ± SEM, n = 3; control versus depleted
TMPro at 4 hours p<0.001, ANOVA. (C–E) Effect of tumor cell injection (2×105/mouse) on
platelet PS exposure, p = 0.0024, ANOVA (C), counts, (D) and circulating platelet-
leukocyte aggregates p<0.0001, ANOVA (E) evaluated after 2 hours with the depicted
number of animals. Control experiments in TMPro/PAR1−/− mice showed that platelet
responses were independent of PAR1 signaling, as expected.
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Fig. 3. Enhanced metastasis in TMPro mice is independent of platelet GPIbα interaction with
CD11b
(A) Metastasis of 2 × 105 or 8 × 104 PyMT-TFflox cells injected into WT or TMPro mice,
respectively, following treatment with anti-CD11b antibody M1/70 or isotype control rat
IgG2b; or (B) of 8 × 104 PyMT-TFflox cells injected into TMPro mice following blockade of
PSGL-1 or PSGL-1 and CD11b. (C) Platelet counts following depletion with anti-mouse
GPIbα antibody 5A7 and transfusion of platelets with human GPIbα (6.2 × 108 platelets/
mouse) or an IL-4R chimeric receptor (4.8 × 108 platelets/mouse), mean ± SEM, n = 4. (D)
Tumor cell retention quantified by real-time PCR 24 hours after injection of 5 × 105 PyMT-
TFflox cells into untreated or platelet-depleted WT mice; *p<0.001, t-test. (E) Metastasis
following injection of 2 × 105 PyMT-TFflox cells after platelet reconstitution of WT mice
with 6 × 108 platelets/mouse; no Plts versus control p<0.01, versus hGPIbα Plts p<0.001,
versus IL-4R Plts p<0.05. Metastasis following injection of 8 × 104 PyMT-TFflox cells into
TMPro mice reconstituted with 4 × 108 platelets/mouse; no Plts versus control or hGPIbα
Plts p<0.001, versus IL-4R Plts p<0.01; ANOVA with Bonferroni post test.
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Fig. 4. Endothelial cell thrombin signaling targets are not required for metastasis in TMPro mice
(A) Metastasis following injection of PyMT-TFflox cells is not increased in EPCRlow mice.
(B) Deletion of the thrombin target gene Slc7a2 does not reduce metastasis in TMPro mice.
Metastases numbers and appearance in WT, EPCRlow, Slc7a2−/−, TMPro, TMPro/Slc7a2−/−,
and platelet-depleted TMPro mice; * p<0.001; ANOVA. Results for TMPro and TMPro/
Slc7a2−/− mice were confirmed in an independent experiment. (C) Metastasis in WT and
PAR1−/− mice. (D) Metastasis of PyMT-TFflox cells in TMPro and TMPro/PAR1−/− mice.
These results were independently reproduced.
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Fig. 5. Redundant roles of tumor and host PAR1 signaling in enhanced metastasis in TMPro
mice
(A) TF and integrin β1 levels of PyMT-PAR1−/− lines derived from two independent tumor-
bearing mice (PAR1−/−b, PAR1−/−c) determined by Western blotting. (B) TF activity of
PAR1−/− lines determined by FXa generation assay. (C) FACS analysis of TF expression by
PAR1−/−b, and PAR1−/−c cells. (D) Metastasis in WT or TMPro mice following injection of
2 × 105 PAR1−/−b and PAR1−/−c cells or 8 × 104 PyMT-TFflox cells (WT), *p<0.001 t-test.
(E) Effect of host PAR1-deficiency on metastasis of 5×105 PAR1−/−c cells injected into WT
or PAR1−/−mice. (F) Effect of host PAR1-deficiency on metastasis of 2 × 105 PAR1−/−c
cells injected into TMPro or TMPro/PAR1−/− mice; *p = 0.027, **p=0.019, t-test. In a third
experiment with smaller groups, a similar trend was observed.
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